crinetics pharmaceuticals san diego logo web
  • Pipeline
    • Research Pipeline
    • Paltusotine
    • CRN04777, Oral SST5 Agonist
    • CRN04894, Oral ACTH Antagonist
    • Oral PTH Antagonist
  • Patients
    • Clinical Trials
    • Patient Videos
      • Clinical Trials
      • Acromegaly in a Pandemic
      • Acromegaly Symptoms
      • Acromegaly Diagnosis
      • Acromegaly Advocate
      • Acromegaly Support
    • PATHFNDR
  • Professionals
    • Acromegaly
    • Congenital Hyperinsulinism
    • Carcinoid Syndrome
    • PATHFNDR
  • Investors
    • Overview
    • Corporate Presentation
    • SEC Filings
    • Stock Information
    • Corporate Governance
    • Press Releases
    • Events & Presentations
    • Analyst Coverage
    • Investor Resources
  • About Us
    • Employee Spotlight
    • Community
  • Careers
    • Culture
    • Job Listings
    • Benefits
  • Contact
    • Contact Us
    • Partnering
    • Grants and Funding
https://crinetics.com/wp-content/uploads/2022/01/808-rotation-d3-header-optimized.mp4

Board of Directors


Board of Directors


Stephen Kaldor, Ph.D.


Board Member

Stephen Kaldor, Ph.D. has served on our board of directors since October 2015. Dr. Kaldor has over 25 years of experience in the biotech and pharmaceutical industries. He currently serves as a director and Chief Executive Officer of Fount Therapeutics, LLC. Dr. Kaldor previously served as President and Chief Executive Officer at Quanticel Pharmaceuticals Inc., from February 2011 until its acquisition by Celgene Corporation in October 2015. Dr. Kaldor was also a venture partner at Versant Ventures from January 2011 until October 2015. Prior to that, Dr. Kaldor served as President and Chief Executive Officer of Ambrx Inc., a biotechnology company. from July 2007 to June 2010. He was the President and Chief Scientific Officer at Syrrx Inc., from March 2003 until its acquisition by Takeda San Diego, Inc., in March 2005, and he continued on as President and Chief Scientific Officer until July 2007.

Dr. Kaldor has served on the board of directors of Resolute Therapeutics, Inc., since October 2016, as a strategic advisor to FronThera US Pharmaceuticals LLC, since March 2016 and as a scientific advisory board member of Crown Bioscience, Inc., since January 2009. Previously, Dr. Kaldor served as a director of Furiex Pharmaceuticals, Inc., from November 2010 until its acquisition by Forest Laboratories, Inc., and as a director of Amira Pharmaceuticals, Inc., from March 2008 until its acquisition by Bristol-Myers Squibb Company in 2011. He started his career at Eli Lilly and Company in 1990 and is a chemist by training.

He holds a B.A. in chemistry from Columbia University and a Ph.D. in organic chemistry from Harvard University.

Back

Subscribe


The Better Bulletin, our periodic newsletter, helps you stay informed on our work to improve the lives of patients living with rare endocrine diseases.

Add Me
Name
Hidden
Confirmation(Required)
This field is for validation purposes and should be left unchanged.
crinetics logo full uai
  • Pipeline
  • Patients
  • Professionals
  • Press
  • Financials
  • Presentation
  • Events
  • Contact
  • Partnering
  • Careers
  • Culture
  • Job Listings
  • About
  • Terms
  • Privacy

  • Crinetics Facebook
  • Crinetics Twitter
  • Crinetics LinkedIn

(858) 450-6464 · 10222 Barnes Canyon Road, Building 2, San Diego, CA 92121
Crinetics Pharmaceuticals, Inc. © 2023 All rights reserved

crinetics logo full uai

  • Pipeline
  • Patients
  • Professionals
  • Financials
  • Presentation
  • Press
  • Events
  • Careers
  • Culture
  • Job Listings
  • About
  • Contact
  • Partnering
  • Privacy
  • Terms
  • Pipeline
  • Patients
  • Professionals
  • Presentation
  • Partnering
  • Financials
  • Press
  • About
  • Contact
  • Careers
  • Privacy
  • Terms

  • Crinetics Facebook
  • Crinetics Twitter
  • Crinetics LinkedIn

(858) 450-6464

10222 Barnes Canyon Road, Building 2,
San Diego, CA 92121

Crinetics Pharmaceuticals, Inc.
© 2023 All rights reserved

Medical Education Grant Application

"*" indicates required fields

MM slash DD slash YYYY
Address*
Therapeutic Area (TA)
Type of Grant

Key Points for Consideration

If your request for support is approved, you will be required to enter into a written grant agreement with Crinetics. Crinetics has drafted the terms of its agreement to be balanced, reasonable and to further the goals of both parties. Negotiating grant agreements requires significant resources, so please ensure that your institution is able and willing to abide by standard agreement terms before proceeding with submission of your application as they will need to be accepted to proceed.
Max. file size: 50 MB.
Signed and dated on your organization’s letterhead

Investigator-Initiated Research Study Application

"*" indicates required fields

MM slash DD slash YYYY
Address*
Therapeutic Area (TA):

Key points for Consideration

If your request for support is approved, you will be required to enter into a written grant agreement with Crinetics. Crinetics has drafted the terms of its agreement to be balanced, reasonable and to further the goals of both parties. Negotiating grant agreements requires significant resources, so please ensure that your institution is able and willing to abide by standard agreement terms before proceeding with submission of your application as they will need to be accepted to proceed.
Max. file size: 50 MB.
Signed and dated on your organization’s letterhead